Aim: In this study, we aimed to evaluate the factors of neoadjuvant chemoradiotherapy (nCRT) affecting the pathologic response in locally advanced rectal cancer. Material and Method: A total of 80 rectal cancer patients undergoing nCRT were included in the study to investigate clinical and pathological factors associated with tumor regression grade. Neoadjuvant rectal scoring (NAR) was calculated to predict overall survival. Results: Thirteen patients (16%) were detected to have pathologic complete response (pCR) and 24 patients (30%) as pathologic poor response (pPR). Tumor size in pCR group was smaller than the in other groups (p=0.003). Distal tumor localization and clinical complete response (cCR) were associated with pCR (p=0.007, p<0.005 respectively). Higher rates of pPR were observed in patients with residual tumours (cPR) (p=0.007). The factors correlated to low NAR were distal tumor localization, pathologically negative lymph nodes, cCR, and pCR (p=0.003, p=0.017, p<0.005, p<0.005 respectively). Statistically significant correlations were identified between high NAR and PET-CT stage III disease (p=0.03), pathologic lymph node metastasis (p<0.005) and cPR (p=0.007). Discussion: Clinical and pathologic factors are correlated with tumour regression grade and 5-year overall survival expectancy. Studies with larger sample sizes are needed to better elucidate these groups of patients and develop more effective treatments.
Introduction
Colorectal cancer is the fourth most common form of cancer worldwide. Rectal cancer represents approximately one-third of all colorectal cancers. More than 90% of all rectal cancers are adenocarcinomas and the primary treatment for a potential curative disease is surgery [1] . Adjuvant therapies should be added following the surgery in patients with risk of local recurrence [2] . Local recurrence significantly decreases with neoadjuvant chemoradiotherapy (nCRT) compared to adjuvant treatment in patients with locally advanced rectal cancer [3] .
Locally advanced rectal cancer patients are typically treated by surgery following preoperative chemoradiotherapy [4] . Studies on rectal cancer requires long-term follow-up since recurrence occurs in the late stage following the treatment, and therefore, an early endpoint with well-established prognostic significance would improve the evaluation of the treatment outcomes in the early period [5] . One of the prognostic factors used for this purpose is the Tumour Regression Grade (TRG), in which grading is performed by comparing the level of fibrosis versus the viable tumor cell counts. Absence of viable tumor cells indicates pathological complete response (pCR), while a dominant tumor without fibrosis indicates a mass poor response (pPR). Longterm outcomes were shown to be better in tumors with pCR than in tumors with pPR [5, 6] .
Valentini et al. developed a nomogram to predict overall survival by investigating the clinical factors in rectal cancer patients who received nCRT [7] . In the subsequent years, using the clinical factors recommended by the nomogram, the neoadjuvant rectal score (NAR) was developed. NAR is important in predicting overall survival in clinical studies. The survival expectancy decreases as NAR increases [8] .
Following nCRT, pPR is the most likely outcome; however, the factors affecting treatment response are not clear. Many studies have investigated pCR-associated factors. The purpose of this study was to investigate the clinical and/or pathological factors that could be used to predict refractory patients with pPR, as well as patients with pCR.
Material and Method
In this study, we included eighty patients with the diagnosis of rectal cancer of clinical stage 2 and 3, who have received nCRT at our clinic between 2013 and 2017. Histopathological diagnosis was confirmed before treatment and pelvic magnetic resonance imaging (MRI) and positron emission tomography (PET-CT) imaging was performed for local regional and distant metastasis staging. In accordance with the American Joint Committee on Cancer (AJCC) seventh edition TNM staging system [9] , clinical stage 2 and 3 patients were included.
All patients had a performance between 0 and 2 according to the Eastern Cooperative Oncology Group (ECOG) scoring system [10] . Patients with an ECOG score ≥3 and stage 4 disease were excluded. The patient files were analyzed retrospectively and information on age, gender, disease stage, and treatment was obtained. The study was approved by the institutional ethics committee.
Radiotherapy:
Patients were immobilized using a belly board in prone position. Computed tomography (CT) (GE-Light Speed 64, GE, US) images were obtained with a 2.5 mm slice thickness, covering the entire pelvis from the upper abdomen to the bottom of the perineum. With the help of the PET-CT and pelvic MRI images, the primary tumour region was contoured as the gross tumour volume (GTV). The clinical tumour volume-1 (CTV-1) was obtained by adding 20 mm margin in all directions to GTV. CTV-2 contained internal iliac, external iliac and all pre-sacral lymph nodes, in addition to CTV-1. Adding a 5mm margin to CTVs, the planning target volume-1 (PTV-1) and PTV-2 were obtained.
The outlined organs at risk (OAR) were the bladder, the bilateral femoral heads, and the small intestine surrounding the PTV-2. For each patient field-in-field (FIF) plan was designed with the CMS-XiO (Elekta®, UK) treatment planning system (TPS).
Three-field FIF plans were performed using 18 MV photons. 45
Gy radiotherapy was administered to PTV-2 with 1.8 Gy fraction dose using 5 days weekly standard fractionation, and a 5.4-9
Gy boost was administered to PTV-1 to complete the total dose to 50.4-54 Gy or a total dose of 25 Gy was administered to PTV-2 in 5 fractions of 5 Gy each for 5 consecutive days. All patients continued treatment without any interruptions.
Chemotherapy:
One of the following chemotherapy regimens was administered concomitantly with radiotherapy: capecitabine 825 mg/ m2, twice daily, 5 days a week, for 5 weeks or 5FU 225 mg/m2 over 24 hours 5 or 7 days/week or bolus 5FU 400mg/m2 plus bolus leucovorin 20 mg/m2, 4 days during week 1 and week 5 of conventional radiotherapy. Chemotherapy was planned in accordance with patient age and ECOG scoring system.
Surgery:
Patients underwent preoperative colonoscopy and/or MRI assessment and then transabdominal resection was performed.
Rectum and the mesorectum, containing the surrounding lymph nodes were extracted with total mesorectal excision. Low anterior resection was performed, leaving a 5 cm margin in the case of proximal tumours and a 2 cm margin in the case of distal tumours. Abdominoperineal resection was performed if a safe 2 cm surgical margin could not be ensured.
Pathology:
A post-operative pathology specimen was investigated by two pathologists. The tumor area was sampled totally and at least 8 Table 1 ). The complete absence of a viable tumor, known as pCR, was recorded as grade 0. If pPR was observed in the treatment-refractory tumors, they were recorded as grade 3.
Neoadjuvant rectal score:
The formula below (eq. 1) is used to calculate NAR.
(1)
Where the pathologic nodal stage (pN) is an element of the set {0, 1, 2}, the clinical tumour stage (cT) is an element of the set {1, 2, 3, 4}, and the pathologic tumour stage (pT) is an element of the set {0, 1, 2, 3, 4}. The results were assessed in 3 groups: low (NAR<8), intermediate (NAR [8] [9] [10] [11] [12] [13] [14] [15] [16] ) and high (NAR>16).
Statistical Analysis:
SPSS version 21 software (IBM Corp., Armonk, NY, USA) was used for the statistical analyses. Chi-Square test of independence, Kruskal-Wallis H test, and Mann-Whitney U test were performed to analyze the variations for tumor regression grades and also to test the correlation of the related factors. A p-value of <0.05 was considered to be statistically significant. Table 3a and 3b.
Results

Patient characteristics are presented in
The mean size of the tumour detected was 5.9 ± 2 cm. Tumour size in pCR group was smaller than the in other groups (p=0.003). In tumors located on the first 10 cm from the anal verge, 12patients (26%) had pCR and 11 patients (23%) had pPR. A statistically significant higher rate of pCR (92%) was observed in distal tumours relative to those located proximally Table 4 . The correlation between PET stage III disease, the presence of residual tumour, pN+ and high NAR was considered statistically significant (p=0.03, p=0.007 and p<0.005 respectively). None of the patients, in whom pCR was obtained, were in the high NAR group (p=0.01). No significant correlation was identified between high NAR and pPR (p=0.6). The factors that were significantly correlated to low NAR were distal tumour localization, pN-, complete clinical response and pCR (p=0.003, p=0.017, p<0.005, p<0.005 respectively).
Discussion
The treatment response differs among patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy. A pathologic complete response is obtained in only 10-30% of the patients. In other patients, treatment response occurs as tumour regression or lack of response [5, 6] . In our study, among the patients who received nCRT, pCR was obtained in 16% (n=13) of the 80 patients and pPR was obtained in 30% of the patients (n=24). The number of patients with no treatment response was 1.8-fold higher than those with complete response. Many studies have previously investigated pCR. However, to the best of our knowledge, no prospective randomized studies have been published on pPR and the factors affecting pPR. In a retrospective study by Kalady et al [12] , 242 patients were grouped as pCR and non-pCR. A time period longer than 8 weeks between radiotherapy and surgery was reported to be factors that affected pCR. Das et al. [13] evaluated 562 patients and detected that a tumor circumferential extending >60% and CEA >2.5 ng/ml were associated with low pCR. Zeng et al. in their study [14] , investigated 323 patients in 2 groups with and without pCR. CEA≤5 ng/ml was reported to significantly increase the pCR rate. Whereas in our study, we investigated the complete and poor response groups based on the pathological tumor regression grade, no correlation could be demonstrated between CEA ≤5 ng/ml and pathologic response (p=0.8). Garland et al [15] investigated pCR-associated clinical factors in 297 patients. A smaller tumor size and pre-treatment nodal stage were described as independent predictors of obtaining pCR. In our study, the mean size of tumour detected were 4.6 ± 1.4 cm in pCR patients and 6.5 ± 2.1 cm in pPR patients. Tumour size in pCR group was smaller than in the other groups (p=0.003). Another factors that affected pCR were distal tumor localization and clinical complete response while the only factor affecting pPR included the presence of residual tumour (p=0.007, p<0.005 and p=0.007, respectively). There was no statistically significant correlation between tumour localization and residual tumour (p=0.12). [7] . Using the neoadjuvant rectal score (NAR) developed using the clinical factors recommended by the nomogram, for patient data from the NSABP R-04 study [8] , a statistically significant correlation between NAR and overall survival (p<0.001) was detected. In the NSABP R04 study, grouping patients into 3 groups as low (NAR<8), intermediate (NAR=8-16) and high (NAR>16), the 5-year survivals were 92%, 89% and 68% respectively (p<0.0001). In the CAO/ARO/AIO-94 (Working Group of Surgical Oncology/Radiation Oncology/Medical Oncology of the German Cancer Society) study [16] , the 10-year survival was reported to be 89.5% in patients with pCR and 39.6% in those with pPR. In a retrospective study performed by Roy et al. [17] , they assessed the utility of pCR and the NAR scoring system to predict disease-free survival (DFS) and overall survival for rectal cancer patients undergoing nCRT. The researchers reported that pCR and lower NAR scores were both associated with significantly longer DFS (p=0.002, p<0.0001 respectively) and overall survival at 5 years (p=0.002, p<0.0001 respectively).
Recently, Fokas et al. [18] investigated the NAR score as a surrogate for DFS in patients with rectal carcinoma treated in the CAO/ARO/AIO-04 randomized phase 3 trial. The results indicated that the NAR score was an independent prognostic factor for DFS and could be used as the primary endpoint in early phase trials. The limitations of our study included the small sample size and the short follow-up. Therefore, no survival data could be achieved. The assessment we made based on NAR values revealed that all but 2 patient with pCR were in the low NAR group (p<0.005). No similar association was detected between pPR and high NAR (p=0.6). Due to its statistically significant correlation to high NAR, our survival expectancy would be low in cases of PET-CT stage 3 disease, the presence of residual tumour and pN+ disease. Following neoadjuvant chemoradiotherapy, tumor localization, PET-CT stage, clinical tumor response, pathologic lymph node status and tumor regression grade can be used as independent clinical predictors of 5-year overall survival expectancy. Small tumor size and distal localization of tumour can be predictors of pathologic complete response. Poor treatment response can be obtained in a statistically significant portion of patients with residual tumor. Studies with a larger sample size are needed to elucidate these patient groups.
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